Click here for Teams Link:

Objectives

  • Identify diagnostic and genetic testing options to evaluate for osteogenesis imperfecta.
  • Recognize the importance of pharmacologic treatment in conjunction with an interdisciplinary approach.

Practice Change

  • Be aware of risk factors for fractures in children with osteogenesis imperfecta.

 

PDF icon “To view additional information on the Nemours Children’s disclosure policy, right click on this link to open in a new window.”

This Microsoft Teams service includes a feature that allows audio and any documents and other materials exchanged or viewed during the session to be recorded. By joining this session, you automatically consent to such recordings. If you do not consent to the recording, discuss your concerns with the meeting host prior to the start of the recording or do not join the session. Please note that any such recordings may be subject to discovery in the event of litigation.

Session date: 
09/11/2024 - 8:00am to 9:00am EDT
Location: 
Add to calendar: 
  • 1.00 MOC ABP - Pediatrics
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Please login or register to take this course.
Faculty List: 
Speaker(s)

Mahim Jain, MD, PhD

has a financial relationship (Professional Services) with Ultragenyx;.
has a financial relationship (Professional Services) with Travere Therapeutics;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Professional Services) with PWN Genomics;.